These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 32569017)

  • 1. Low-Dose Ticagrelor in Patients With High Ischemic Risk and Previous Myocardial Infarction: A Multicenter Prospective Real-World Observational Study.
    Cesaro A; Taglialatela V; Gragnano F; Moscarella E; Fimiani F; Conte M; Barletta V; Monda E; Limongelli G; Severino S; Cirillo P; Calabrò P
    J Cardiovasc Pharmacol; 2020 Aug; 76(2):173-180. PubMed ID: 32569017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk definition and outcomes with the application of the PEGASUS-TIMI 54 trial inclusion criteria to a "real world" STEMI population: results from the Italian "CARDIO-STEMI SANREMO" registry.
    Sanchez F; Boasi V; Vercellino M; Tacchi C; Cannarile P; Pingelli N; Perri D; Gomez L; Cattunar S; Mascelli G
    BMC Cardiovasc Disord; 2021 Mar; 21(1):144. PubMed ID: 33736607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54.
    Dellborg M; Bonaca MP; Storey RF; Steg PG; Im KA; Cohen M; Bhatt DL; Oude Ophuis T; Budaj A; Hamm C; Spinar J; Kiss RG; Lopez-Sendon J; Kamensky G; Van de Werf F; Ardissino D; Kontny F; Montalescot G; Johanson P; Bengtsson O; Himmelmann A; Braunwald E; Sabatine MS
    Eur Heart J Cardiovasc Pharmacother; 2019 Oct; 5(4):200-206. PubMed ID: 31218354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry.
    D'Ascenzo F; Bertaina M; Fioravanti F; Bongiovanni F; Raposeiras-Roubin S; Abu-Assi E; Kinnaird T; Ariza-Solé A; Manzano-Fernández S; Templin C; Velicki L; Xanthopoulou I; Cerrato E; Rognoni A; Boccuzzi G; Omedè P; Montabone A; Taha S; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Blanco PF; Garay A; Quadri G; Varbella F; Queija BC; Paz RC; Fernández MC; Pousa IM; Gallo D; Morbiducci U; Dominguez-Rodriguez A; Valdés M; Cequier A; Alexopoulos D; Iñiguez-Romo A; Gaita F; Rinaldi M; Lüscher TF
    Eur J Prev Cardiol; 2020 May; 27(7):696-705. PubMed ID: 30862233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54.
    Parker WA; Storey RF
    Heart; 2016 May; 102(10):783-9. PubMed ID: 26857211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DAPT Score and the Impact of Ticagrelor Monotherapy During the Second Year After PCI.
    Chichareon P; Modolo R; Kawashima H; Takahashi K; Kogame N; Chang CC; Tomaniak M; Ono M; Walsh S; Suryapranata H; Cotton J; Koning R; Akin I; Kukreja N; Wykrzykowska J; Piek JJ; Garg S; Hamm C; Steg PG; Jüni P; Vranckx P; Valgimigli M; Windecker S; Onuma Y; Serruys PW
    JACC Cardiovasc Interv; 2020 Mar; 13(5):634-646. PubMed ID: 32139222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gut Microbiota-Dependent Trimethylamine N-oxide and Cardiovascular Outcomes in Patients With Prior Myocardial Infarction: A Nested Case Control Study From the PEGASUS-TIMI 54 Trial.
    Gencer B; Li XS; Gurmu Y; Bonaca MP; Morrow DA; Cohen M; Bhatt DL; Steg PG; Storey RF; Johanson P; Wang Z; Hazen SL; Sabatine MS
    J Am Heart Assoc; 2020 May; 9(10):e015331. PubMed ID: 32366163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics and outcomes in patients with a prior myocardial infarction treated with extended dual antiplatelet therapy with ticagrelor 60 mg: findings from ALETHEIA, a multi-country observational study.
    Bonaca MP; Lesén E; Giannitsis E; Hedberg J; Jernberg T; Lambrelli D; Duong M; Maggioni AP; Ariza-Solé A; Ten Berg J; Storey RF
    Eur Heart J Cardiovasc Pharmacother; 2023 Dec; 9(8):701-708. PubMed ID: 37653447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study.
    Bhatt DL; Fox K; Harrington RA; Leiter LA; Mehta SR; Simon T; Andersson M; Himmelmann A; Ridderstråle W; Held C; Steg PG;
    Clin Cardiol; 2019 May; 42(5):498-505. PubMed ID: 30788847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long-Term Ticagrelor in Stable Patients With Prior Myocardial Infarction.
    Magnani G; Ardissino D; Im K; Budaj A; Storey RF; Steg PG; Bhatt DL; Cohen M; Oude Ophius T; Goudev A; Parkhomenko A; Kamensky G; Angiolillo DJ; López-Sendón J; Johanson P; Braunwald E; Sabatine MS; Bonaca MP
    J Am Heart Assoc; 2021 Feb; 10(4):e017008. PubMed ID: 33559485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet function testing guided antiplatelet therapy reduces cardiovascular events in Chinese patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: The PATROL study.
    You J; Li H; Guo W; Li J; Gao L; Wang Y; Geng L; Wang X; Wan Q; Zhang Q
    Catheter Cardiovasc Interv; 2020 Feb; 95 Suppl 1():598-605. PubMed ID: 31957972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Incidence of Cardiovascular Events in Chinese Patients with Acute Coronary Syndrome Treated with Ticagrelor: the 12-Month, Phase IV, Multicenter, Single-Arm DAYU Study.
    Gao R; Wu Y; Liu H; Su G; Yuan Z; Zhang A; Wang Y; Wang Z; Wang Y; Zhang H; Zheng Y; Liu L; Shen L; Leonsson-Zachrisson M; Han Y;
    Cardiovasc Drugs Ther; 2018 Feb; 32(1):47-56. PubMed ID: 29488142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54).
    Bonaca MP; Goto S; Bhatt DL; Steg PG; Storey RF; Cohen M; Goodrich E; Mauri L; Ophuis TO; Ruda M; Špinar J; Seung KB; Hu D; Dalby AJ; Jensen E; Held P; Morrow DA; Braunwald E; Sabatine MS
    Circulation; 2016 Sep; 134(12):861-71. PubMed ID: 27576775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged dual antiplatelet therapy in stable coronary disease: comparative observational study of benefits and harms in unselected versus trial populations.
    Timmis A; Rapsomaniki E; Chung SC; Pujades-Rodriguez M; Moayyeri A; Stogiannis D; Shah AD; Pasea L; Denaxas S; Emmas C; Hemingway H
    BMJ; 2016 Jun; 353():i3163. PubMed ID: 27334486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients With Multivessel Coronary Disease.
    Bansilal S; Bonaca MP; Cornel JH; Storey RF; Bhatt DL; Steg PG; Im K; Murphy SA; Angiolillo DJ; Kiss RG; Parkhomenko AN; Lopez-Sendon J; Isaza D; Goudev A; Kontny F; Held P; Jensen EC; Braunwald E; Sabatine MS; Oude Ophuis AJ
    J Am Coll Cardiol; 2018 Feb; 71(5):489-496. PubMed ID: 29406853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term use of ticagrelor in patients with prior myocardial infarction.
    Bonaca MP; Bhatt DL; Cohen M; Steg PG; Storey RF; Jensen EC; Magnani G; Bansilal S; Fish MP; Im K; Bengtsson O; Oude Ophuis T; Budaj A; Theroux P; Ruda M; Hamm C; Goto S; Spinar J; Nicolau JC; Kiss RG; Murphy SA; Wiviott SD; Held P; Braunwald E; Sabatine MS;
    N Engl J Med; 2015 May; 372(19):1791-800. PubMed ID: 25773268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical relevance of ticagrelor monotherapy following 1-month dual antiplatelet therapy after bifurcation percutaneous coronary intervention: Insight from GLOBAL LEADERS trial.
    Kogame N; Chichareon P; De Wilder K; Takahashi K; Modolo R; Chang CC; Tomaniak M; Komiyama H; Chieffo A; Colombo A; Garg S; Louvard Y; Jüni P; G Steg P; Hamm C; Vranckx P; Valgimigli M; Windecker S; Stoll HP; Onuma Y; Janssens L; Serruys PW
    Catheter Cardiovasc Interv; 2020 Jul; 96(1):100-111. PubMed ID: 31410968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk.
    Baber U; Leisman DE; Cohen DJ; Gibson CM; Henry TD; Dangas G; Moliterno D; Kini A; Krucoff M; Colombo A; Chieffo A; Sartori S; Witzenbichler B; Steg PG; Pocock SJ; Mehran R
    Circ Cardiovasc Qual Outcomes; 2019 Jan; 12(1):e004945. PubMed ID: 30606052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of dual antiplatelet therapies after coronary endarterectomy combined with coronary artery bypass grafting: a cohort study.
    Yan H; Tiemuerniyazi X; Song Y; Xu F; Feng W
    J Cardiothorac Surg; 2020 Jun; 15(1):155. PubMed ID: 32600365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease.
    Bonaca MP; Bhatt DL; Storey RF; Steg PG; Cohen M; Kuder J; Goodrich E; Nicolau JC; Parkhomenko A; López-Sendón J; Dellborg M; Dalby A; Špinar J; Aylward P; Corbalán R; Abola MTB; Jensen EC; Held P; Braunwald E; Sabatine MS
    J Am Coll Cardiol; 2016 Jun; 67(23):2719-2728. PubMed ID: 27046162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.